Seòmar agus comataidhean

(a) In 2014, the Deputy First Minister committed to re-opening the Fund and provided £5.5 million per annum to enable ILF to re-open to new applicants for the first time since 2010.Through an extensive process of co-production, the ILF Scotland Transition Fund was developed as an alternative to re-opening the 2015 Fund. The Transition Fund was designed to support young disabled people with the transition to adult life. This entirely new fund opened to applications in December 2017.

(b) The Cabinet Secretary wrote to the ILF Scotland Board on 16 December 2022, 26 January 2023 and 27 February 2023 stating his support for ILF Scotland but indicating that re-opening the 2015 Fund could only progress when affordability and sustainability could be assured.

The Minister for Mental Wellbeing and Social Care wrote to the Chair of ILF Scotland’s Advisory Group on 23 January 2023 stating that he remains committed to re-opening the 2015 Fund but is unable to do so due to financial constraints.

Improving access for women to appropriate support, speedy diagnosis and best treatment for endometriosis is one of the priorities set out in the Women’s Health Plan for 2021-24.  

To ensure that those with endometriosis are receiving consistent and appropriate care we will help to support implementation the Modernising Patient Pathways Programme’s (MPPP) new Integrated Endometriosis Referral Care Pathway for NHS Scotland, which is now approved and will be circulated to all NHS Scotland Health Boards this year.  

In August 2021, we published an NHS Recovery Plan which set out our plans and ambitions over a five year period and is backed by more than £1 billion of funding. The plan supports an increase in inpatient, day case, and outpatient activity to address the backlogs of care, which will be supported by the implementation of sustainable improvements and new models of care.  

In recognition of the pressure faced by colposcopy services, last year we provided over £660,000 additional funding to NHS Ayrshire & Arran, NHS Greater Glasgow & Clyde, NHS Highland, NHS Lothian and NHS Tayside to support capacity. The funding was used to enhance capacity through recruitment and additional clinics, including at weekends, to allow increased activity and reduce demand on consultant time.  

Whilst Scottish Government do not hold the information requested centrally, we are progressing work to allow Boards to automatically gather this.

The published budget for 2022-23 was £53.3 million. ILF Scotland’s Grant-in-Aid allocation for 2022-23 was £52.72 million. Of this, £48.45 million was allocated to the Independent Living Fund and £4.27 million for the Transition Fund which was launched in December 2017. Funds are provided in response to need and therefore there can be a difference between published budget and final spending.

The Independent Living Fund was transferred to ILF Scotland on 1st July 2015, and at that time:

(a) 2,812 people resident in Scotland were in receipt of the Fund.

(b) The total budget to continue financial awards for people resident in Scotland for the remainder of the financial year 2015-16 was £36.34 million (equivalent to a full year cost of £48.45 million).

We know that endometriosis can have a significant impact on people’s lives, and that support for those with the condition is required while we work to improve waiting times.  

To ensure those with endometriosis are receiving consistent and appropriate care we will help support The Modernising Patient Pathways Programme (MPPP) to implement the new Integrated Endometriosis Referral Care Pathway for NHS Scotland, which has now been approved and will be circulated to all NHS Scotland health boards this year.  

We have invested in research into endometriosis, which is vital to help us achieve better care for those with the condition. We are jointly funding a £250,000 endometriosis research project with Wellbeing of Women and the recipient of the grant will be announced later in March. The research aims to develop improvements into treatment and management options for the condition.  

To ensure that people with endometriosis have access to the most accurate and relevant information and links to further support, we updated the NHS Inform endometriosis page. This includes videos to support those with the condition and to provide information about symptoms and treatment options available.  

The supply of medicines is a reserved matter for the UK Government. Scottish Government officials are regularly updated on any supply disruptions which may arise and will provide advice to the NHS in Scotland on options to address any shortages.      

The Scottish Government, as Sponsor, works closely with ILF Scotland on financial monitoring to ensure that funds are available to meet operational requirements whilst not being provided in advance of need or building up large reserves balances. This is consistent with the Scottish Public Finance Manual. In the current financial year, the Scottish Government has provided £47.72 million to ILF Scotland which covers the funding requirement for 2022-23. Financial reserves, held by ILF Scotland that are in excess of minimum requirements, have been used in addition to funds made available by the Scottish Government to meet operational demands.

In partnership with the Scottish Strategic Network for Genomics Medicine (SSNGM), we have been developing our Strategic Intent for Genomics Medicine which will be published in the coming weeks.

While early in its’ development, we will also publish our first Genomics Strategy for Scotland and associated implementation plan in the course of 2023.

The Scottish Government recognises that an improved streamlined process for the implementation of new genetic tests linked to a Scottish Medicines Consortium (SMC) approved medicine is required. The SMC currently provides early information to National Services Division (NSD) on cancer medicines in clinical development that are expected to require a companion diagnostic through regular horizon scanning reports. To support financial and service planning, the SMC also provides Health Boards – in confidence - with information on medicines that may require a companion diagnostic through regular Forward Look reports, which include emerging new medicines, including Advanced Therapy Medicinal Products (ATMPs).

A key function of the Scottish Strategic Network for Genomics Medicine (SSNGM) is to horizon scan for new medicines to prevent delays for patients getting access to advanced therapies. To support this, the SSNGM has established Scottish Genomics Testing Assessment Groups (SGTAG) for cancer and rare disease. The SGTAG will work with the SMC and others to approve the availability of companion diagnostic tests in the genetic laboratories.

Official statistics for the Scottish Cervical Screening Programme will be published this Spring, with data up to March 2022. It is therefore too early to assert what uptake for 2021/22 will show, however the Scottish Government is aware that previous years have highlighted the need to improve uptake.

Both the Scottish Government and the Cervical Screening Programme encourage all those eligible for cervical screening to go for a test when invited, and for all those eligible to take up the offer of the HPV vaccine when invited to.

We continue to work with Jo’s Cervical Cancer Trust to support their vital campaign work on cervical cancer, having awarded £456,000 in funding to highlight the benefits of screening and to better understand barriers to uptake.

Finally, we understand that increasing uptake alone is not enough, and that we must also strive for equality of uptake. Work is currently underway on a national Equity in Screening Strategy, which is being led by National Screening Oversight. The strategy will provide a focus and commitment to tackle inequalities in screening, to achieve equity of access for all eligible individuals across the whole screening pathway. It will consider the main causes of inequalities and will outline initial actions to address barriers and facilitate access of underserved groups.